TRACON Pharmaceuticals Announces a Strategic Licensing Collaboration for Two Janssen Oncology Assets and a $5 Million Equity Investment from Johnson & Johnson Innovation – JJDC, Inc.
September 28, 2016 08:00 ET
|
TRACON Pharmaceuticals, Inc.
Strategic Transaction Validates TRACON’s Unique Clinical Development Capabilities $5 Million Equity Investment Strengthens TRACON’s Balance Sheet SAN DIEGO, Sept. 28, 2016 (GLOBE NEWSWIRE) --...
TRACON Pharmaceuticals to Present at Upcoming Investment Conferences
August 31, 2016 16:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Aug. 31, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
August 10, 2016 16:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Aug. 10, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON to Report Second Quarter 2016 Company Highlights and Financial Results on August 10, 2016
August 03, 2016 16:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Aug. 03, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Announces Positive Results from TRC105 and TRC102 Clinical Trials at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
June 06, 2016 08:00 ET
|
TRACON Pharmaceuticals, Inc.
Median PFS greater than 12 months with continued durable complete responses observed in angiosarcoma patients treated with TRC105 and Votrient® in Phase 1b/2 trial Partial responses seen in solid...
TRACON Pharmaceuticals to Present at Upcoming Investment Conferences
May 31, 2016 16:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, May 31, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Reports Granting of Inducement Award
May 20, 2016 16:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, May 20, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Initiates Dosing in Phase 1b/2 Study of TRC105 in Patients with Hepatocellular Carcinoma
May 18, 2016 16:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, May 18, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals to Present at the UBS Global Healthcare Conference
May 16, 2016 16:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, May 16, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
May 11, 2016 16:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, May 11, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...